Significant
Progress with Novel Diabetic Eye Disease Portfolio
Positive Topline
Results from Phase 1/2 evaluating THR-317 for treatment of
DME
Multiple Clinical
Readouts Expected towards the end of H2 2019
Total Cash &
Investments at €85.1 million on 31 December 2018
Highlights
Pipeline
-
In April 2018, Oxurion reported positive Day90
(30 days after last injection) data from its Phase 1/2 clinical
study evaluating THR-317 (anti-PlGF) for the treatment of DME:
results showed safety and tolerability of THR-317 for intra-ocular
use, and 30% of anti-VEGF treatment naïve patients showed >15
letter vision gain in BCVA (Best Corrected Visual Acuity)
-
In April 2018, the first patient was enrolled in
a Phase 2 study evaluating the efficacy and safety of THR-317 in
combination with ranibizumab (Lucentis®), for the treatment of
DME
-
In May 2018, the first patient was enrolled in a
Phase 1 open-label, multicenter, dose escalation study evaluating
the safety of THR-149 for treatment of DME
-
In July 2018, Oxurion reported positive Day150
data from its Phase 1/2 clinical study evaluating THR-317 for
treatment of DME: the data confirmed the safety and tolerability of
THR-317 for intra-ocular use, and that it could improve visual
acuity for up to Day 90 after the last injection
-
In September 2018, the first patient was
enrolled in Phase 1 clinical study evaluating THR-687, a novel
pan-RGD integrin antagonist, for treatment of DME
-
In September 2018, the first patient was
enrolled in Phase 2 clinical study evaluating THR-317 for treatment
of Idiopathic Macular Telangiectasia Type 1 (MacTel 1)
-
The on-going clinical studies of all 4 drug
candidates are expected to read out data towards the end of the
second half of 2019
-
In November 2018, Oxurion signed a strategic
research collaboration with Beta Therapeutics to develop new
heparanase inhibitors for the treatment of retinal disorders such
as dry age-related macular degeneration (AMD)
Corporate
developments and Appointments
-
In September 2018, the Company rebranded as
Oxurion NV. As a result, the Company's stock ticker is OXUR.BR
(EURONEXT Brussels)
-
In October 2018, Oxurion announced the
appointment (co-opting) of Adrienne Graves to
its Board of Directors, replacing Paul Howes
Financial
-
Oxurion generated Jetrea® sales
of €5.2 million in 2018, compared to €4.6 million in 2017
-
Total revenue amounted to €5.3 million in 2018
compared to €9.1 million in 2017. The variance is due to a €3.2
million one-off positive settlement for cost of goods in 2017 and a
reduction in Jetrea® royalty
income of €1.2 million
-
At the end of December 2018, Oxurion had €85.1
million in cash and investments, compared to €115.7 million
(including restricted cash) as of the end of December 2017
Leuven, Belgium,
7 March 2019 - Oxurion NV (Euronext Brussels: OXUR), a
biopharmaceutical company developing innovative treatments to
preserve vision in patients with diabetic eye disease, today issues
a business update and its financial update for the year ending
December 31, 2018.
Oxurion is developing a highly
competitive pipeline of disease modifying drug candidates for
diabetic eye disease, particularly diabetic retinopathy (DR) and
diabetic macular edema (DME), two key areas of unmet medical
need.
The Oxurion clinical development
pipeline consists of distinct products with different modes of
action, and includes:
THR-317 -
PIGF (human placental growth factor) neutralizing monoclonal
antibody, is in a Phase 2 study evaluating the efficacy and safety
of intravitreal THR-317 when administered in combination with
ranibizumab (Lucentis®), for the
treatment of DME. Results from this Phase 2 study are expected
towards the end of 2019.
In addition, THR-317 is being
evaluated in a Phase 2 study for the treatment of Idiopathic
Macular Telangiectasia Type 1 (MacTel 1). MacTel 1 is a rare
disease that affects the macula and can lead to vision loss. First
data from this study is expected towards the end of 2019.
THR-149 - is
a potent plasma kallikrein inhibitor being developed for the
treatment of DME. THR-149 is in a Phase 1 open-label, multicenter,
dose escalation study. Results from this study are anticipated
towards the end of 2019.
THR-687 - is
a small molecule pan-RGD integrin antagonist being developed to
treat a broad range of patients with diabetic eye disease. THR-687
entered the clinic in September 2018. Results from this Phase 1
study are expected towards the end of 2019.
Patrik De
Haes, MD, CEO of Oxurion nv, commented: "We are very pleased with the progress that we have made
with our innovative clinical pipeline of novel drug candidates
targeting diabetic eye disease. Diabetic eye disease is a growing
global healthcare problem where there is a clear need for improved
treatment options. 2019 is an important year for Oxurion as we
expect to announce clinical data from 3 key on-going studies: a
Phase 2 trial with THR-317, in combination with Lucentis®
in patients with DME, as well as two Phase 1 studies evaluating
THR-687 and THR-149 respectively. We are confident these data will
demonstrate the potential of our candidates, provide the
information we need to plan the next stages of their clinical
development and deliver significant value to our
shareholders."
Pioneering New
Therapies for Diabetic Eye Disease
Diabetes is a major global
healthcare problem with an estimated 425 million adults living with
diabetes worldwide. This number is expected to increase to over 625
million by 2045, according to the International Diabetes
Federation.
Diabetic eye disease is caused by
hyperglycemia (high blood glucose levels) associated with diabetes.
If left unchecked hyperglycemia causes damage to the capillaries in
the back of the eye (retina), which can result in vision loss and
subsequently blindness.
Diabetic retinopathy (DR) is a
serious sight-threatening disease and the leading cause of vision
loss among working-age adults, affecting over a third of all people
with diabetes. DR progresses from mild, non-proliferative to more
severe or even proliferative stages.
Diabetic macular edema (DME) is a
severe complication of DR. DME is an accumulation of fluid in the
macula - the part of the retina that controls detailed vision - due
to leaking blood vessels. DME represents an area of unmet medical
need as the current standard of care treatment with anti-VEGFs has
been shown to deliver suboptimal results in a significant number of
patients.
Oxurion Clinical
and Pre-clinical Development Update
THR-317 - a Humanized mAb Against
Human PlGF for treatment of DME
THR-317 (anti-PlGF) is a
recombinant humanized monoclonal antibody directed against the
receptor-binding site of human placental growth factor (PlGF) being
developed for the treatment of DME. In pre-clinical models,
anti-PlGF has been shown, in addition to anti-angiogenic and
anti-edema properties, to be anti-inflammatory.
Positive Topline
Day90 and Day150 data reported from a Phase 1/2 study evaluating
THR-317 for treatment of DME
In April 2018, Oxurion announced
positive Day 90 topline clinical data from its Phase 1/2 clinical
study evaluating THR-317 for the treatment of Diabetic Macular
Edema (DME).
The results of the study, which was primarily a safety study,
clearly demonstrated the safety and tolerability of THR-317 for
intra-ocular use. Moreover, the reported Day90 data from the study
also indicated that 30% of anti-VEGF treatment naïve patients
(n=90) had a 3 line or more (>15 letters) gain in Best Corrected
Visual Acuity (BCVA) after 3 monthly injections with THR-317
(8mg)
These positive data were further
reinforced by the Day 150 topline clinical data that were announced
in July. The Day 150 study results (3 months after the last
injection) not only confirmed the safety and tolerability of
THR-317 for intra-ocular use, they also showed that 30% of the 8mg
anti-VEGF treatment naïve group still showed > 10 letters vision
gain, and 10% showed a > 15 letters vision gain, indicating a
durability of effect.
A Phase 2
Clinical study evaluating THR-317 in combination with ranibizumab (Lucentis®), an
anti-VEGF
Encouraged by the positive Day 90
topline study results, Oxurion initiated a Phase 2 study evaluating
THR-317 in combination with an anti-VEGF.
In April 2018, the first patient
was recruited in a Phase 2 study evaluating the efficacy and safety
of intravitreal THR-317 administered in combination with
ranibizumab (Lucentis®) a VEGF
inhibitor, for the treatment of DME. Initial results from this
Phase 2 clinical study are anticipated towards the end of 2019.
It is believed that simultaneously
inhibiting VEGF (ranibizumab) and PlGF (THR-317) could deliver
better efficacy than either treatment alone. Non-clinical
experiments indicate that anti-PlGF in the presence of an anti-VEGF
antibody has an additive effect inhibiting the growth of new blood
vessels (Van de Veire et al.,2010), a
disease hallmark of DME.
In addition, THR-317 could bring
the advantage of reduced inflammation associated with a reduced
level of PIGF activity (van Bergen et
al., 2017).
Results from this Phase 2 trial
will provide the clinical data to inform the next stages of
THR-317's clinical development.
At the Euretina International Congress in Vienna
(Austria) in September, Oxurion gave a presentation on Anti-inflammatory effects of the PlGF neutralizing antibody
THR-317 in patients with diabetic macular edema, providing
further scientific findings supporting therapeutic potential of
THR-317 as a promising new therapy for Diabetic Eye Disease.
A Phase 2 clinical study
evaluating THR-317 for treatment of MacTel1
In September, Oxurion started a
Phase 2 open-label multi-center study evaluating the efficacy and
safety of intravitreal THR-317 for the treatment of Macular
Telangiectasia Type 1 (MacTel 1). MacTel 1 is a rare disease that
affects the macula and can lead to vision loss. There is currently
no cure or effective treatment for MacTel 1.
This Phase 2 study plans to enroll
10 patients with macular edema caused by MacTel 1, who will each
receive three 8mg intravitreal THR-317 injections over a period of
2 months. Efficacy and safety of the therapy will be assessed via
functional and anatomic endpoints.
Oxurion is undertaking this study
as part of its mission to enhance vision and fight blindness,
alongside the development of its diabetic eye disease pipeline.
Initial results from this clinical
study are anticipated towards the end of 2019.
A Phase 1 study
evaluating THR-149, a Potent Plasma Kallikrein inhibitor, for the
treatment of DME
THR-149 is a novel plasma
kallikrein inhibitor, generated using Bicycle Therapeutics'
Bicycles® technology platform, that is being developed for the
treatment of DME.
THR-149 acts through inhibition of
the Plasma Kallikrein-Kinin (PKaI-kinin) system, which is
considered a validated target for DME.
This is because activation of the
PKal-kinin system has been shown to induce retinal vascular
permeability, inflammation and angiogenesis. Based on literature
data, patients with DME have elevated levels of plasma kallikrein,
and therefore a plasma kallikrein inhibitor may be appropriate for
the treatment of these patients.
Preclinical studies involving
THR-149 were published in The Journal of Medicinal
Chemistry in March 2018 and presented by Oxurion's senior
scientist Dr Tine Van Bergen at the Annual Meeting 2018 of the
European Association for the Study of Diabetes Eye Complications
Study Group (EASDec). The data demonstrate the potency and efficacy
of bicyclic peptide inhibitors of pKal, such as THR-149, via a
VEGF-independent pathway.
In May 2018, Oxurion initiated a
Phase 1 clinical study evaluating the safety of a single
intravitreal injection of escalating dose levels of THR-149 in
patients with DME.
A maximum of 15 patients will be
enrolled, with initial results anticipated around the end of the
second half of 2019.
A Phase 1 study
evaluating THR-687, a novel pan-RGD integrin antagonist for the
treatment of DME
Oxurion is developing THR-687, a
novel pan-RGD integrin antagonist (inhibitor), to preserve vision
of a broad range of patients with diabetic eye disease. This broad
potential is based on the hypothesis that integrin inhibition can
target multiple processes involved in pathological angiogenesis and
vascular leakage in patients with eye disease. Oxurion is
initially developing THR-687 for DME.
In September 2018, THR-687 entered
the clinic in a Phase 1 open-label, multicenter, dose escalation
study evaluating the safety of a single intravitreal injection of
THR-687 for the treatment of patients with DME. A maximum of 15
patients will be enrolled, with initial results anticipated by the
end of 2019.
During the Euretina International
Congress in Vienna (Austria) in September 2018, preclinical data
were presented supporting the therapeutic potential of THR-687 as a
novel treatment for sight-threatening DR.
Strategic
Collaboration with Beta Therapeutics to develop new heparanase
inhibitors for the treatment of retinal disorders
On November 5th 2018,
Oxurion signed a strategic research collaboration with Beta
Therapeutics to develop new heparanase inhibitors for the treatment
of retinal disorders such as dry age-related macular degeneration
(AMD).
Heparanase is an endoglycosidase
playing an important role in modifying the extracellular matrix and
in inflammatory processes. In the retina, heparanase has been
associated with DR and potentially with AMD pathogenesis.
Under the terms of the agreement
Oxurion has an exclusive option to license in the heparanase
inhibitor program.
Oncurious -
developing next generation immuno-oncology therapies
Oncurious is developing
next-generation immuno-oncology drugs targeting a broad spectrum of
cancers. Oncurious is a majority owned subsidiary of Oxurion. The
remainder of the shares in the company are owned by VIB, a leading
life sciences research institute, based in Flanders, Belgium.
Recruitment is on-going in a US
Phase 1/2a study with Oncurious' lead program TB-403, a humanized
monoclonal antibody against placental growth factor (PlGF). The
study aims to recruit 27 patients with Relapsed or Refractory
Medulloblastoma. For recruiting patients, Oncurious is partnering
with Beat Childhood Cancer, an international group of researchers
and hospitals dedicated to finding a way to stop childhood cancers.
The purpose of this study is to
evaluate the safety and tolerability of TB-403 at the maximum
tolerated dose in pediatric subjects with relapsed or refractory
Medulloblastoma. TB-403 is being developed by Oncurious in
conjunction with BioInvent International.
The study is currently enrolling
the 4th and last
cohort of patients. Initial data from this study are anticipated
towards the end of 2019.
JETREA®
- a first-in-class drug for symptomatic VMA treatment
Oxurion has demonstrated its
ability to discover, develop and bring to market innovative
ophthalmology therapies, with its product JETREA®. This
first-in-class therapeutic for the treatment for symptomatic
vitreomacular adhesion and traction, has been used to treat over
30,000 patients worldwide since it was first launched in 2013.
On 15 September 2018, the return
of ex-US commercialization rights to Oxurion NV (from Novartis AG)
was finalized. Global ownership and product responsibility of
JETREA® is currently with Oxurion NV. The JETREA®
commercial activities, with continued direct or indirect
distribution of JETREA® in selected
markets, are operated from Leuven, Belgium.
New Board
Member
In October 2018, Oxurion appointed
(co-opted) Adrienne Graves, Ph.D., to its
board of directors. Dr. Graves replaced Paul Howes.
Dr. Graves is a board member of
multiple companies and organizations including Akorn Inc., Nicox,
the American Society of Cataract and Refractive Surgery, the
Glaucoma Research Foundation, and the American Academy of
Ophthalmology. She was the president and chief executive officer of
Santen Inc., the U.S. arm of Japan's largest ophthalmic
pharmaceutical company, Santen Pharmaceutical Co., Ltd. Dr. Graves
was the director of international ophthalmology at Alcon
Laboratories, Inc.
Rebranding
In September 2018, the Company
rebranded as Oxurion NV.
The name Oxurion better reflects
the Company's ambition to deliver best in class therapies for back
of the eye disorders. The decision to rebrand reflected the
significant progress the Company has made in progressing its
competitive pipeline on novel drug candidates targeting diabetic
eye disease.
Financial
Update
Oxurion generated Jetrea sales of
€5.2 million in 2018, compared to €4.6 million in 2017.
Total revenue amounted to €5.3
million in 2018 compared to €9.1 million in 2017. The variance is
due to the receipt of a €3.2 million one-off positive settlement
for cost of goods in 2017 and a reduction in Jetrea royalties
income of €1.2 million.
As a consequence, the Group reported a gross profit of €2.0 million
in 2018. This compares with a gross profit of €6.5 million in
2017.
In 2018, Oxurion's R&D
expenses were €29.5 million. This compares to €23.2 million in
2017. This increase is due to the start of clinical trials. These
new studies are in addition to the ongoing studies that were
initiated in 2017. Both years include a €3.2 million amortization
of the intangible assets related to Jetrea® (VMA/VMT
indication).
Selling and marketing expenses
were €6.2 million in 2018. This compares to €4.2 million in 2017.
This higher spend is due to the Company regaining of the global
commercialization rights of Jetrea®.
General and administrative
expenses amounted to €6.3 million in 2018 compared to €6.2 million
in 2017.
The reported net loss for 2018 was
€38.7 million resulting in negative diluted earnings per share of
€1.01. In 2017, as a result of other operating income of €50.5
million, the Company reported a net profit of €22.6 million
resulting in €0.62 diluted earnings per share.
Oxurion's cash position (including
investments) at the end of 2018 amounted to €85.1 million. This
compares to €115.7 million (including investments and restricted
cash) at the end of 2017.
END
For further
information please contact:
Oxurion
NV
Wouter Piepers
Global Head of Investor Relations & Corp Coms
+32 16 75 13 10 / +32 478 33 56 32
wouter.piepers@oxurion.com
|
EU - Citigate Dewe Rogerson
David Dible / Sylvie Berrebi
+44 20 7638 9571
oxurion@citigatedewerogerson.com |
US - LifeSci Public Relations
Alison Chen
+1 646 876 4932
achen@lifescipublicrelations.com
|
About Oxurion
Oxurion (Euronext Brussels: OXUR)
is a biopharmaceutical company currently developing a competitive
pipeline of disease-modifying drug candidates for diabetic eye
disease, a leading cause of blindness in people of working age
worldwide.
Oxurion's most advanced drug
candidate is THR-317, a PlGF inhibitor for the treatment of
diabetic macular edema (DME), which is currently in a Phase 2 study
in combination with Lucentis®. THR-317 is
also being evaluated in a Phase 2 study for the treatment of
Idiopathic Macular Telangiectasia Type 1 (MacTel 1), a rare retinal
disease that affects the macula and can lead to vision loss.
Oxurion has two further pipeline
candidates, THR-149, a plasma kallikrein inhibitor being developed
for the treatment of DME; and THR-687, a pan-RGD integrin
antagonist in development for the treatment of diabetic retinopathy
and DME. Both THR-149 and THR-687 are in Phase 1 clinical
studies.
Oxurion is headquartered in Leuven, Belgium, and
is listed on the Euronext Brussels exchange under the symbol
OXUR.
More information is available at
www.oxurion.com.
Important information about forward-looking
statements
Certain
statements in this press release may be considered
"forward-looking". Such forward-looking statements are based on
current expectations, and, accordingly, entail and are influenced
by various risks and uncertainties. The Company therefore cannot
provide any assurance that such forward-looking statements will
materialize and does not assume an obligation to update or revise
any forward-looking statement, whether as a result of new
information, future events or any other reason. Additional
information concerning risks and uncertainties affecting the
business and other factors that could cause actual results to
differ materially from any forward-looking statement is contained
in the Company's Annual Report. This press
release does not constitute an offer or invitation for the sale or
purchase of securities or assets of Oxurion in any
jurisdiction. No securities of Oxurion may be offered or sold
within the United States without registration under the U.S.
Securities Act of 1933, as amended, or in compliance with an
exemption therefrom, and in accordance with any applicable U.S.
state securities laws.
Financial information
2018
Consolidated statement of profit and loss |
|
|
|
|
|
In '000 euro (for the year ended 31 December) |
2018 |
2017 |
|
|
|
Income |
5,320 |
9,055 |
Sales |
5,221 |
4,552 |
Income
from royalties |
99 |
1,258 |
Settlement
on previous years COGS |
0 |
3,245 |
Cost of sales |
-3,355 |
-2,579 |
Gross profit |
1,965 |
6,476 |
Research
and development expenses |
-29,523 |
-23,186 |
General
and administrative expenses |
-6,349 |
-6,226 |
Selling
expenses |
-6,217 |
-4,247 |
Other
operating income |
883 |
50,449 |
Operating result |
-39,241 |
23,266 |
Finance
income |
796 |
392 |
Finance
expense |
-324 |
-1,029 |
Result before income tax |
-38,769 |
22,629 |
Taxes |
-10 |
-14 |
Result of the year |
-38,779 |
22,615 |
|
|
|
Attributable to: |
|
|
Equity
holders of the company |
-38,474 |
22,788 |
Non-controlling interest |
-305 |
-173 |
|
|
|
Result per share |
|
|
Basic
earnings / loss (-) per share (euro) |
-1.01 |
0.63 |
Diluted
earnings / loss (-) per share (euro) |
-1.01 |
0.62 |
|
|
|
In '000
euro (as at 31 December) |
2018 |
2017 |
Result of the year |
-38,779 |
22,615 |
Exchange
differences on translation of foreign operations |
62 |
-150 |
Other comprehensive income, net of income tax |
62 |
-150 |
Other
comprehensive income that will not be reclassified to profit or
loss |
62 |
-150 |
Total comprehensive loss (-) / income for the year |
-38,717 |
22,465 |
Attributable to: |
|
|
Equity
holders of the company |
-38,412 |
22,638 |
Non-controlling interest |
-305 |
-173 |
|
|
|
|
|
|
|
Consolidated statement of financial
position |
|
|
|
|
|
In '000
euro (as at 31 December) |
2018 |
2017 |
|
|
|
ASSETS |
|
|
Property, plant and equipment |
614 |
991 |
Intangible assets |
20,450 |
23,603 |
Other non-current assets |
127 |
126 |
Non-current tax credit |
2,584 |
1,434 |
Non-current assets |
23,775 |
26,154 |
Inventories |
1,036 |
2,204 |
Trade and other receivables |
4,219 |
4,295 |
Current tax receivable |
707 |
2,054 |
Investments |
20,475 |
49,555 |
Cash and cash equivalents |
64,652 |
56,175 |
Restricted cash |
0 |
10,000 |
Current assets |
91,089 |
124,283 |
Total assets |
114,864 |
150,437 |
|
|
|
EQUITY AND LIABILITIES |
|
|
Share capital |
137,564 |
151,991 |
Share premium |
13 |
157,661 |
Cumulative translation differences |
-273 |
-335 |
Other reserves |
-12,563 |
-13,141 |
Retained earnings |
-19,853 |
-163,546 |
Equity attributable to equity holders of the
company |
104,888 |
132,630 |
Non-controlling interest |
422 |
727 |
Total equity |
105,310 |
133,357 |
Trade payables |
5,054 |
3,298 |
Other short-term liabilities |
4,500 |
13,782 |
Current liabilities |
9,554 |
17,080 |
Total equity and liabilities |
114,864 |
150,437 |
|
|
|
5.3. Consolidated statement of cash flows |
|
|
|
|
|
In '000
euro (for the year ended 31 December) |
2018 |
2017 |
|
|
|
Cash flows from operating activities |
|
|
Profit
(loss) for the period |
-38,779 |
22,615 |
Finance
expense |
324 |
1,029 |
Finance
income |
-796 |
-392 |
Depreciation of property, plant and equipment |
474 |
674 |
Amortization of intangible fixed assets |
3,153 |
3,156 |
Equity
settled share-based payment transactions |
592 |
176 |
Decrease
in trade and other receivables including tax receivables and
inventories |
1,441 |
3,734 |
Increase /
decrease (-) in short-term liabilities |
2,474 |
-4,697 |
Net cash flows generated / used (-) in
operating activities |
-31,116 |
26,295 |
|
|
|
Cash flows from investing activities |
|
|
Disposal
of property, plant and equipment (following a sale) |
98 |
323 |
Decrease /
Increase (-) in investments |
29,066 |
-27,738 |
Interest
received and similar income |
141 |
22 |
Purchase
of property, plant and equipment |
-195 |
-246 |
Purchase /
divestment (-) of other non-current assets |
-1 |
76 |
Net cash flows generated / used (-) in
investing activities |
29,109 |
-27,562 |
|
|
|
Cash flows from financing activities |
|
|
Restricted
cash reserved for issue of share capital |
0 |
10,000 |
Proceeds
from capital and share premium increases from exercise of
warrants |
92 |
0 |
Paid
interests |
-8 |
-11 |
Net cash flows generated in financing
activities |
84 |
9,989 |
|
|
|
Net change in cash and cash equivalents |
-1,924 |
8,722 |
Net cash,
cash equivalents and restricted cash at the beginning of the
period |
66,175 |
58,251 |
Effect of
exchange rate fluctuations |
401 |
-798 |
Net cash and cash equivalents at the end of the
period |
64,652 |
66,175 |
Consolidated statement of changes in
equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share capital |
Share premium |
Cumulative translation differences |
Other reserves |
Retained earnings |
Attributable to equity holders of the company |
Non-controlling interest |
Total |
Balance as at 1 January 2017 |
151,991 |
157,661 |
-185 |
-13,317 |
-186,334 |
109,816 |
43 |
109,859 |
Profit of
the year 2017 |
0 |
0 |
0 |
0 |
22,788 |
22,788 |
-173 |
22,615 |
Change to
foreign currency translation difference and revaluation
reserve |
0 |
0 |
-150 |
0 |
0 |
-150 |
0 |
-150 |
Issue of
ordinary shares |
0 |
0 |
0 |
0 |
0 |
0 |
857 |
857 |
Share-based payment transactions |
0 |
0 |
0 |
176 |
0 |
176 |
0 |
176 |
Balance as at 31 December 2017 |
151,991 |
157,661 |
-335 |
-13,141 |
-163,546 |
132,630 |
727 |
133,357 |
|
|
|
|
|
|
|
|
|
Balance as at 1 January 2018 |
151,991 |
157,661 |
-335 |
-13,141 |
-163,546 |
132,630 |
727 |
133,357 |
Result of
the year 2018 |
0 |
0 |
0 |
0 |
-38,474 |
-38,474 |
-305 |
-38,779 |
Change to
foreign currency translation difference and revaluation
reserve |
0 |
0 |
62 |
0 |
0 |
62 |
0 |
62 |
Net change
in fair value of investments |
0 |
0 |
0 |
-14 |
0 |
-14 |
0 |
-14 |
Issue of
ordinary shares |
9,875 |
217 |
0 |
0 |
0 |
10,092 |
0 |
10,092 |
Capital
decrease |
-24,302 |
-157,865 |
0 |
0 |
182,167 |
0 |
0 |
0 |
Share-based payment transactions |
0 |
0 |
0 |
592 |
0 |
592 |
0 |
592 |
Balance as at 31 December 2018 |
137,564 |
13 |
-273 |
-12,563 |
-19,853 |
104,888 |
422 |
105,310 |
The statutory
auditor, BDO Bedrijfsrevisoren represented by Gert Claes, has
confirmed that the audit procedures, which have been substantially
completed, have not revealed any material adjustments which would
have to be made to the accounting data included in the Company's
annual announcement, and intends to issue an unqualified
opinion.
This
announcement is distributed by West Corporation on behalf of West
Corporation clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Oxurion NV via Globenewswire
Thermon (NYSE:THR)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Thermon (NYSE:THR)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024